Policy
And Advocacy
To advance our goal of improving the lives of people affected by psoriasis and psoriatic arthritis in Canada, CPN is committed to providing input through government and other relevant consultations on issues that matter to our community. Thank you to everyone who helps to inform our submissions by responding to CPN surveys.
2022
Joint feedback on Health Canada's consultation regarding a handbook for healthcare professionals on biosimilar biologic drugs
May 2022
2021
Disability Inclusion Action Plan joint submission by CPN and CAPP
September 2021
CADTH Feedback on Scoping Document: Utilization of Biologic Disease-Modifying Antirheumatic Drugs for Plaque Psoriasis
August 2021
CADTH Feedback on Scoping Document: Formulary Management of Biologics in Plaque Psoriasis
2021
Written Submission to the Pre-Budget Consultations
February 2021
CPN Key Biosimilar Policy Considerations
January 2021
2020
Patented Medicine Prices Review Board (PMPRB)
August 4 2020
Canadian Pain Taskforce Submission
May 29 2020
2019
Home Narrowband Ultraviolet B Phototherapy
November 14 2019